# Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

> **NCT00280176** · PHASE1 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** bortezomib
- **DRUG:** fluorouracil
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00280176
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2008-11
- **Final completion:** 2010-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2012-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280176, "Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00280176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*